Skip to main content
Top
Published in: Rheumatology International 9/2008

01-07-2008 | Original Article

Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone density

Authors: Efrat Arnheim, Gaya Chicco, Mici Phillips, Ehud Lebel, A. Joseph Foldes, Menachem Itzchaki, Deborah Elstein, Ari Zimran, Gheona Altarescu

Published in: Rheumatology International | Issue 9/2008

Login to get access

Abstract

Bone-related complications in Gaucher disease are considered to be poorly responsive to specific enzyme replacement therapy. Polymorphisms of candidate genes associated with low bone density were investigated to see whether they are correlated with bone mineral density (BMD) and bone involvement in Gaucher disease. Genotyping for polymorphisms in candidate genes (interleukins 1α and 1β, interleukin-1 receptor antagonist; cytochrome P450; collagen 1A1; low-density Lipoprotein Receptor; bone morphogenic protein 4; vitamin D receptor; and estrogen receptor 2β) were performed using standard methodologies. BMD was measured by dual energy X-ray absorptiometry (DXA). One hundred and ninety-four patients and 100 controls were genotyped for the above polymorphisms. Thirteen haplotypes were obtained, with several correlations with BMD in patients; also, a haplotype (T889-T3954-C511-240VNTR of IL1) was significantly correlated with T-scores and Z-score for femur neck and lumbar spine (p = 0.01) in patients. Haplotypes of bone-specific candidate genes associated with BMD may predict severity of these features in Gaucher disease.
Literature
1.
go back to reference Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Baudelet A, Sly SW, Valle D (eds) The metabolic and molecular bases of inherited disease. 3rd edn. McGraw Hill, New York, pp 3635–3668 Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Baudelet A, Sly SW, Valle D (eds) The metabolic and molecular bases of inherited disease. 3rd edn. McGraw Hill, New York, pp 3635–3668
2.
go back to reference Grabowski GA, Horowitz M (1997) Gaucher’s disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol 10:635–656PubMedCrossRef Grabowski GA, Horowitz M (1997) Gaucher’s disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol 10:635–656PubMedCrossRef
3.
go back to reference Stowens DW, Teitelbaum SL, Kahn AJ, Barranger J (1985) Skeletal complications of Gaucher disease. Medicine (Baltimore) 64:310–322 Stowens DW, Teitelbaum SL, Kahn AJ, Barranger J (1985) Skeletal complications of Gaucher disease. Medicine (Baltimore) 64:310–322
4.
go back to reference Moreno ML, Crusius JB, Cherñavsky A, Sugai E, Sambuelli A, Vazquez H, et al (2005) The IL-1 gene family and bone involvement in celiac disease. Immunogenetics 57:618–620PubMedCrossRef Moreno ML, Crusius JB, Cherñavsky A, Sugai E, Sambuelli A, Vazquez H, et al (2005) The IL-1 gene family and bone involvement in celiac disease. Immunogenetics 57:618–620PubMedCrossRef
5.
go back to reference McDowell TL, Symons JA, Ploski R, Forre O, Duff GW (1995) A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 38:221–228PubMedCrossRef McDowell TL, Symons JA, Ploski R, Forre O, Duff GW (1995) A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 38:221–228PubMedCrossRef
6.
go back to reference di Giovine FS, Takhsh E, Blakemore AI, Duff GW (1992) Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1:450PubMedCrossRef di Giovine FS, Takhsh E, Blakemore AI, Duff GW (1992) Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1:450PubMedCrossRef
7.
go back to reference Guasch JF, Bertina RM, Reitsma PH (1996) Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 8:598–602PubMedCrossRef Guasch JF, Bertina RM, Reitsma PH (1996) Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 8:598–602PubMedCrossRef
8.
go back to reference Napoli N, Villareal DT, Mumm S, Halstead L, Sheikh S, Cagaanan M et al. (2005) Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 20:232–239PubMedCrossRef Napoli N, Villareal DT, Mumm S, Halstead L, Sheikh S, Cagaanan M et al. (2005) Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 20:232–239PubMedCrossRef
9.
go back to reference Garcia-Giralt N, Nogués X, Enjuanes A, Mellibovsky L, Nogues X, Carreras R et al (2002) Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density. J Bone Miner Res 17:384–393PubMedCrossRef Garcia-Giralt N, Nogués X, Enjuanes A, Mellibovsky L, Nogues X, Carreras R et al (2002) Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density. J Bone Miner Res 17:384–393PubMedCrossRef
10.
go back to reference Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523PubMedCrossRef Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523PubMedCrossRef
11.
go back to reference Hogan BL (1996) Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 10:1580–1594PubMedCrossRef Hogan BL (1996) Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 10:1580–1594PubMedCrossRef
12.
go back to reference Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan BL (1996) Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis. Development 122:1693–1702PubMed Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan BL (1996) Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis. Development 122:1693–1702PubMed
13.
go back to reference Shearman AM, Karasik D, Gruenthal KM, Demissie S, Cupples LA, Housman DE (2004) An ESR2 CA repeat polymorphism, D14S1026, was associated with BMD. J Bone Miner Res 19:773–781PubMedCrossRef Shearman AM, Karasik D, Gruenthal KM, Demissie S, Cupples LA, Housman DE (2004) An ESR2 CA repeat polymorphism, D14S1026, was associated with BMD. J Bone Miner Res 19:773–781PubMedCrossRef
14.
go back to reference Valdivielso JM, Fernandez E (2006) Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 371:1–12PubMedCrossRef Valdivielso JM, Fernandez E (2006) Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 371:1–12PubMedCrossRef
15.
go back to reference Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1989) Prediction of severity of Gaucher’s disease by identification of mutations at DNA level. Lancet 2:349–352PubMedCrossRef Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1989) Prediction of severity of Gaucher’s disease by identification of mutations at DNA level. Lancet 2:349–352PubMedCrossRef
16.
go back to reference Pastores GM, Wallenstein S, Desnick RJ, Luckey MM (1996) Bone density in type 1 Gaucher disease. J Bone Miner Res 11:1801–1807PubMedCrossRef Pastores GM, Wallenstein S, Desnick RJ, Luckey MM (1996) Bone density in type 1 Gaucher disease. J Bone Miner Res 11:1801–1807PubMedCrossRef
17.
go back to reference Erbas B, Ristevski S, Poon C, Yeung S, Ebeling PR (2007) Decreased spinal and femoral neck volumetric bone mineral density (BMD) in men with primary osteoporosis and their first-degree male relatives: familial effect on BMD in men. Clin Endocrinol (Oxf) 66:78–84 Erbas B, Ristevski S, Poon C, Yeung S, Ebeling PR (2007) Decreased spinal and femoral neck volumetric bone mineral density (BMD) in men with primary osteoporosis and their first-degree male relatives: familial effect on BMD in men. Clin Endocrinol (Oxf) 66:78–84
18.
go back to reference Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lwik CW, Hamersma H et al (2005) Bone mineral density in sclerosteosis; affected individuals and gene carriers. Clin Endocrinol Metab 90:6392–6395CrossRef Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lwik CW, Hamersma H et al (2005) Bone mineral density in sclerosteosis; affected individuals and gene carriers. Clin Endocrinol Metab 90:6392–6395CrossRef
19.
go back to reference Lebel E, Itzchaki M, Hadas-Halpern I, Zimran A, Elstein D (2001) Outcome of total hip arthroplasty in patients with Gaucher disease. J Arthroplasty 16:7–12PubMedCrossRef Lebel E, Itzchaki M, Hadas-Halpern I, Zimran A, Elstein D (2001) Outcome of total hip arthroplasty in patients with Gaucher disease. J Arthroplasty 16:7–12PubMedCrossRef
Metadata
Title
Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone density
Authors
Efrat Arnheim
Gaya Chicco
Mici Phillips
Ehud Lebel
A. Joseph Foldes
Menachem Itzchaki
Deborah Elstein
Ari Zimran
Gheona Altarescu
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 9/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0550-7

Other articles of this Issue 9/2008

Rheumatology International 9/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine